Tp53 gene mediates distinct dopaminergic neuronal damage in different dopaminergic neurotoxicant models
- PMID: 29089978
- PMCID: PMC5649453
- DOI: 10.4103/1673-5374.215243
Tp53 gene mediates distinct dopaminergic neuronal damage in different dopaminergic neurotoxicant models
Abstract
Tp53, a stress response gene, is involved in diverse cell death pathways and its activation is implicated in the pathogenesis of Parkinson's disease. However, whether the neuronal Tp53 protein plays a direct role in regulating dopaminergic (DA) neuronal cell death or neuronal terminal damage in different neurotoxicant models is unknown. In our recent studies, in contrast to the global inhibition of Tp53 function by pharmacological inhibitors and in traditional Tp53 knock-out mice, we examined the effects of DA-specific Tp53 gene deletion after 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine and methamphetamine exposure. Our data suggests that the Tp53 gene might be involved in both neuronal apoptosis and neuronal terminal damage caused by different neurotoxicants. Additional results from other studies also suggest that as a master regulator of many pathways that regulate apoptosis and synaptic terminal damage, it is possible that Tp53 may function as a signaling hub to integrate different signaling pathways to mediate distinctive target pathways. Tp53 protein as a signaling hub might be able to evaluate the microenvironment of neurons, assess the forms and severities of injury incurred, and determine whether apoptotic cell death or neuronal terminal degeneration occurs. Identification of the precise mechanisms activated in distinct neuronal damage caused by different forms and severities of injuries might allow for development of specific Tp53 inhibitors or ways to modulate distinct downstream target pathways involved.
Keywords: 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Parkinson's disease; Tp53; apoptosis; methamphetamine; neurotoxicity.
Conflict of interest statement
Conflicts of interest: None declared.
Figures
Similar articles
-
Dopaminergic neuron-specific deletion of p53 gene is neuroprotective in an experimental Parkinson's disease model.J Neurochem. 2016 Sep;138(5):746-57. doi: 10.1111/jnc.13706. Epub 2016 Jul 15. J Neurochem. 2016. PMID: 27317935 Free PMC article.
-
Acetylcholinesterase deficiency decreases apoptosis in dopaminergic neurons in the neurotoxin model of Parkinson's disease.Int J Biochem Cell Biol. 2013 Feb;45(2):265-72. doi: 10.1016/j.biocel.2012.11.015. Epub 2012 Nov 29. Int J Biochem Cell Biol. 2013. PMID: 23201480
-
Early signs of neuronal apoptosis in the substantia nigra pars compacta of the progressive neurodegenerative mouse 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine/probenecid model of Parkinson's disease.Neuroscience. 2006 Jun 19;140(1):67-76. doi: 10.1016/j.neuroscience.2006.02.007. Epub 2006 Mar 14. Neuroscience. 2006. PMID: 16533572
-
JNK inhibition as a potential strategy in treating Parkinson's disease.Drug News Perspect. 2004 Dec;17(10):646-54. doi: 10.1358/dnp.2004.17.10.873916. Drug News Perspect. 2004. PMID: 15696229 Review.
-
Estrogen, neuroinflammation and neuroprotection in Parkinson's disease: glia dictates resistance versus vulnerability to neurodegeneration.Neuroscience. 2006;138(3):869-78. doi: 10.1016/j.neuroscience.2005.07.060. Epub 2005 Dec 5. Neuroscience. 2006. PMID: 16337092 Review.
Cited by
-
RIP3/MLKL-mediated neuronal necroptosis induced by methamphetamine at 39°C.Neural Regen Res. 2020 May;15(5):865-874. doi: 10.4103/1673-5374.268902. Neural Regen Res. 2020. PMID: 31719251 Free PMC article.
-
Uncovering the mechanism of the effects of Paeoniae Radix Alba on iron-deficiency anaemia through a network pharmacology-based strategy.BMC Complement Med Ther. 2020 Apr 28;20(1):130. doi: 10.1186/s12906-020-02925-4. BMC Complement Med Ther. 2020. PMID: 32345291 Free PMC article.
-
Identifying methamphetamine use predictors in HIV infection: Immune-dopaminergic signatures in peripheral leukocytes and the role of COMT genotype.Brain Behav Immun Health. 2024 Oct 5;42:100873. doi: 10.1016/j.bbih.2024.100873. eCollection 2024 Dec. Brain Behav Immun Health. 2024. PMID: 39430881 Free PMC article.
-
Neuronally enriched microvesicle RNAs are differentially expressed in the serums of Parkinson's patients.Front Neurosci. 2023 Jul 6;17:1145923. doi: 10.3389/fnins.2023.1145923. eCollection 2023. Front Neurosci. 2023. PMID: 37483339 Free PMC article.
-
Integrated multi-omics approach identified molecular mechanism and pathogenetic processes of COVID-19 that affect patient with Parkinson's disorder.Saudi J Biol Sci. 2021 Dec;28(12):6939-6945. doi: 10.1016/j.sjbs.2021.07.074. Epub 2021 Aug 2. Saudi J Biol Sci. 2021. PMID: 34366686 Free PMC article.
References
-
- Agrawal S, Singh A, Tripathi P, Mishra M, Singh PK, Singh MP. Cypermethrin-induced nigrostriatal dopaminergic neurodegeneration alters the mitochondrial function: a proteomics study. Mol Neurobiol. 2015;51:448–465. - PubMed
-
- Biswas SC, Ryu E, Park C, Malagelada C, Greene LA. Puma and p53 play required roles in death evoked in a cellular model of Parkinson disease. Neurochem Res. 2005;30:839–845. - PubMed
-
- Borlongan CV, Wang Y, Su TP. Delta opioid peptide (D-Ala 2, D-Leu 5) enkephalin: linking hibernation and neuroprotection. Front Biosci. 2004;9:3392–3398. - PubMed
-
- Burke RE. Programmed cell death in Parkinson's disease. Handb Clin Neurol. 2007;83:591–605. - PubMed
Publication types
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials
Miscellaneous